Mr. Robert von der Porten reports

MEDX HEALTH CORP. ANNOUNCES THIRD QUARTER 2014 FINANCIAL RESULTS AND THE GRANTING OF STOCK OPTIONS

MedX Health Corp. has released its results for the three and nine months ended Sept. 30, 2014, which are also available on SEDAR.

The company reported revenues of $295,247 for the third quarter of 2014, or 270 per cent of the prior year's sales level of $109,296, an increase of $185,951. Of the increase, $108,358 was from the company's SIAscopy product line, with the rest of the increase from its therapeutic laser products. The company reported income for the three months ended Sept. 30, 2014, of $342,733, or nil per share, compared with a loss of $362,456, or one cent per share, for the three months ended Sept. 30, 2013. Income for the quarter was due to higher sales, and also from the reversal of previously recorded liabilities.

For the nine-month period to Sept. 30, 2014, the company reported income of $64,029, or nil per share, compared with a loss of $885,935, or two cents per share, for the 2013 period. Revenues of $673,038 for the first nine months of 2014 were 60 per cent higher than revenue of $419,090 in 2013.

"We believe we have made substantial progress in the business. Our focus on building sales and developing longer-term opportunities for our skin cancer screening technology is starting to show results," said Rob von der Porten, MedX's chief executive officer. "Our SIAscopy devices are now employed in well over 100 pharmacies in Norway and Sweden, and with our business partners we are working to grow this channel, as it allows consumers easier access to skin assessment, and yields recurring revenue based on each consumer assessment. In addition, we continue to build our distribution channels to medical practitioners, including Australia, where we recently gained certification. We are also committed to improving the company's financial stability as we continue to seek additional capital."

The company also announces that it has granted a total of 7.15 million incentive stock options to management and consultants, of which 4,697,693 are vested, with the remainder vesting over a period of 18 months. The options are exercisable at 10 cents for a period of five years from the date of the granting of the options.

We seek Safe Harbor.